Purpose: We evaluated the efficacy and tolerability of the ketogenic diet (KD) on generalised convulsions and status epilepticus (SE) in patients with Dravet syndrome (DS). Methods: Patients with DS having ≥2 generalised convulsions/month despite drug treatment were included in this study and placed on a KD for 6 months. From 3 months before (baseline) to 6 months after KD initiation, caregivers recorded patients' seizure activity, antiepileptic drug use, and adverse events. The KD efficacy was determined by examining the frequency and duration of seizures at 3 and 6 months vs. baseline. Responders were defined as individuals whose generalised convulsions decreased in frequency by ≥50% vs. baseline. Seizures lasting ≥5 min and SE were specifically evaluated. Patients' cognition was also assessed at 3 and 6 months via questionnaire. Results: Twenty patients continued the KD for at least 3 months. Of the 17 responders identified at month 3, seizures decreased by 50-89% and 90-99% in nine and two patients, respectively; six patients were seizure free. The KD was ineffective in three patients, who discontinued the diet. By month 6, seizures decreased by 50-89% and 90-99% in six and one patient(s), respectively; 10 patients were seizure free. The frequency of other seizure types also improved. During all 6 months, neither generalised convulsions lasting ≥5 min nor SE was detected in the 17 responders. The KD also improved patients' cognition. Conclusion: The KD is a good treatment option for medically intractable epilepsy.
Introduction
Dravet syndrome (DS), initially known as severe myoclonic epilepsy in infancy(SMEI), was first described by Dravet more than 30 years ago [1] . With an estimated incidence of 1 in 20,000-40,000 children, DS is a rare form of epilepsy, and is accompanied by impaired psychomotor and neurologic development, occurring in the first year of life in apparently normal infants. [2, 3] . Further, DS is a representative type of channelopathy, which in most cases is caused by a mutation in SCN1A, a sodium channel gene. Sodium channels allow sodium to pass to the inside of the cell and play a key role in a cell's ability to generate and transmit electrical signals. Therefore, mutations in this gene alter the cell's ability to transmit electrical signals, ultimately producing the seizures that are characteristic of epilepsy [1] .
Patients with DS have multiple seizure types, are present throughout the evolution in all patients. Among the various seizure types, brief seizures are those lasting < 5 min, prolonged seizures are those lasting ≥5 min, and status epilepticus (SE) is defined as seizures lasting > 30 min. Once a seizure lasts ≥5 min, it is likely to be further prolonged and is difficult to terminate. Generally, treatment protocols have used 5 min as the point at which action is required in order to minimise the risk of seizures reaching 30 min, as such seizures may lead to permanent neuronal injury and adverse outcomes.
Among the known electroclinical syndromes, DS is one of the most challenging diseases to treat, particularly owing to the high likelihood of recurrent SE in patients with this syndrome. Treating SE is particularly important, as the occurrence of multiple SE episodes during infancy is reportedly followed by cognitive and behavioural impairment in up to 80% of patients with DS. Once a seizure lasts more than 5 min, it is likely to be prolonged. So, status treatment protocols use a 5-minute definition to minimize the risk of seizures reaching 30 min, which could reduce emergency and nerve injury due to SE. Hence, the management strategy for patients with DS is to significantly reduce seizure frequency and duration, particularly general convulsion prolonged seizures of ≥5 min in duration and SE. Another therapeutic goal is to minimise comorbidities, including intellectual disability, behavioural and psychiatric problems, and seizure-related injury [4] .
Unfortunately, few antiepileptic drugs (AEDs) are effective for DS. Although valproate or clobazam is typically used as a first-line drug to manage and prevent seizures, these agents are usually insufficient when administered alone [4] . Thus, topiramate, levetiracetam, bromide, and/ or a ketogenic diet (KD) are often employed as adjunctive therapies, and have been shown to provide substantial efficacy [5] . Triple therapy, which includes clobazam, valproate, and stiripentol, is currently regarded as the 'gold standard' treatment for DS [6] . However, stiripentol and clobazam are not currently available in the domestic market in China. Lamotrigine, carbamazepine, and high doses of intravenous phenobarbital should be avoided because they can aggravate seizures and even induce SE [5] . As such, therapeutic strategies that can reduce rather than aggravate seizures in patients DS are sorely needed.
The KD has been widely and successfully used to treat children with drug-resistant epilepsy since the 1920s [7] . The KD is high in fat but low in carbohydrates, and thus ketone bodies become the main fuel supplying the brain's energy demand [8] . Research supports that the KD can effectively control the seizures that are associated with DS [9] . Approximately two-thirds of patients respond to the KD. In 2013, Laux and Blackford [10] demonstrated that 13 out of 20 (65%) patients with DS who were on the KD experienced a > 50% reduction in seizure frequency. And a reduction in seizures of > 90% was noted in 6 out of 20 (30%) patients with DS. In 2015, Dressler et al. [11] reported an overall long-term response rate of 60% in patients with DS who were placed on the KD. At 3 months, 7 out of 10 (70%) patients were responders which were defined as the absolute reduction in seizure frequency of ≥50% three months after initiation of a new treatment compared with "baseline'', and one child achieved a seizure-free status. At 6 months, 6 out of 10 (60%) patients were still responsive to the KD [11] . Further, a study in mice with Scn1a mutations showed that the KD elevated the seizure thresholds of the mice [12] . Although the evidence is promising, additional studies on the efficacy and tolerability of the KD in Chinese patients with DS are required before its use can become standard in this country.
The aim of this study was to investigate the efficacy and tolerability of the KD for 6 months in Chinese patients with DS. Specifically, we focused on the effect of KD on generalised convulsion frequency, duration of general convulsion prolonged seizures lasting ≥5 min and SE, cognitive function, and adverse events.
Methods

Patients
Twenty patients who had ≥2 generalised convulsions per month despite appropriate AED use were considered for enrolment in the study. The patients were diagnosed with DS at the Department of Neurology of the Children's Hospital of Fudan University between December 1, 2014, and December 1, 2016. The diagnostic criteria for DS included the following: (1) the onset is early (before 1 year of age), (2) the seizure type is clonic and often unilateral instead of generalized tonic or tonic-clonic, (3) the seizure episodes are more prolonged and frequent, even when treated, and (4) the body temperature is not very high. The diagnosis can be established if other seizure types (myoclonic seizures -atypical absences, partial seizures, obtundation status) or photically induced spike-waves appear; but some DS, namely, borderline SMEI which have discovered an SCN1A gene mutation in patients without myoclonias [13, 14] . Patients' guardians provided informed consent for them to participate; this study was approved by the Medical Ethics Committee of the Children's Hospital of Fudan University, Shanghai, China.
KD treatment
In patients with metabolic disorders such as pyruvate carboxylase deficiency, fatty acid oxidation may be worsened by the KD. Therefore, urine, plasma metabolism, and serum lactate tests were performed to rule out the presence of such disorders in all patients prior to KD initiation. The KD was implemented by a multidisciplinary team including physicians, nurses, and nutritionists.
The children were gradually started on the classic 4:1 ketogenic ratio (ratio of grams of fat to grams of carbohydrate plus protein) according to the Johns Hopkins protocol and the guidelines for infants with refractory epilepsy [15] . Additional calcium supplements and sugar-free, fat-soluble vitamin and mineral supplements were also administered to the children each day. We monitored the patients' height, weight, blood glucose levels, blood ketone levels, and blood lipid levels, as well as performed ultrasounds of the urinary system, electrocardiograms, and electroencephalograms regularly during hospitalisation and throughout the follow-up period [16] .
Children were followed up over the phone by our dietician during the first month and returned to the KD outpatient clinic for follow-up visits 1, 3, and 6 months after diet initiation. Parents could also communicate with each other and consult the doctors via WeChat.
Criteria for efficacy evaluation
For patients with DS, it is vital that the seizure frequency and duration be reduced, particularly general convulsion prolonged seizures of ≥5 min in duration and SE [4] . The frequency and duration of generalised convulsions were evaluated based on recordings in caregiver's seizure calendar. The seizure frequency at 3 and 6 months after KD initiation were compared with the seizure frequency during the 3-month baseline period before KD initiation [6] . The percentage decrease in generalised convulsions frequency from baseline was used to assess the efficacy of the diet. The judgment of efficacy was divided into four levels as follows: decreased by < 50%, decreased between ≥50% and 89%, decreased between ≥90% and 99%, and decreased by 100% (free of generalised convulsions). Responders were defined as those individuals whose generalised convulsion seizures decreased in frequency by at least 50% at 3 or 6 months compared to the frequency at baseline. Additionally, generalised convulsions lasting ≥5 min and SE were compared before and after KD. For other seizure types, such as atypical absence and myoclonic seizures, the caregivers estimated the KD efficacy without exact seizure counts, and patients were divided into two classes based on these estimations, i.e. improvement or no effect. Adverse events associated with the diet were noted at diet initiation and at all follow-up visits. Data are presented as the mean (standard deviation, SD) or percentages.
Cognitive function evaluation
At least two guardians for each subject were asked to independently judge the changes in several cognitive functions, i.e. attention, alertness, and memory, by completing a questionnaire at 3 and 6 months after KD initiation. The evaluation results were classified as no change, improvement, or regression (Table 1) . Cognitive function was considered improved only when both guardians selected improvement [17] .
Results
General characteristics of the patients
Twenty children (12 boys and 8 girls) were enrolled in this study (Table 2) . Genetic testing revealed SCN1A mutations in all patients, including nine missense mutations, four nonsense mutations, one insertional mutation, five deletions, and one splicing mutation. The mean age at seizure onset was 6.25 (range, 1-9) months, and the mean age of the participants was 45.05 (range, 9-141) months. Before KD initiation, the children experienced a mean of 12 (range, 2-90) generalised convulsions per month, and the mean number of different types of AEDs was 2.30 (range, 2-4) categories.
The first convulsive seizures began during the first year of life and tended to be prolonged, with 9 of the 20 (45%) patients showing seizures triggered by fever. Patients with DS showed multiple seizure types. Generalised convulsions were found in all 20 (100%) patients, myoclonic seizures occurred in 17 (85%) patients, atypical absence seizures occurred in 10 (50%) patients, atonic seizures occurred in 5 (25%) patients, partial seizures occurred in 17 (85%) patients, and 15 (75%) patients had at least one episode of SE. All 20 patients had general convulsions that lasted for ≥5 min. Partial seizures manifested as either versive seizures or clonic jerks limited to a limb or a hemiface, or a combination of the two.
AED, antiepileptic drug; KD, ketogenic diet; M, male; F, female, VPA, valproic acid; LEV, levetiracetam; TPM, topiramate; CZP, clonazepam; GTCS, generalised tonic-clonic seizures; PS, partial seizure; SE, status epilepticus; MY, myoclonic seizures; AA, absence seizures; AT, atonic seizures. Response was defined as those individuals whose generalised convulsion seizures decreased in frequency by at least 50% at 3 or 6 months compared to the frequency at baseline.
Efficacy of the KD
In our study, patients showed good compliance with the KD treatment. All 20 patients remained on the KD for at least three months. At 3 months after KD initiation, the outcome of generalised convulsion frequency, decreased by ≥50% in 17 patients (responders, Table 2 ). Of these responders, the generalised convulsion frequency decreased by 50-89% and 90-99% in nine and two patients, respectively, and six patients were seizure free. At 3 months, 55% (11/20) of patients also exhibited improvement in the frequency of other seizure types. Unfortunately, the KD was ineffective or was associated with worsened seizures in three patients, and these patients discontinued the KD. At 6 months, generalised convulsions were still decreased by ≥50% in 17 patients, with six and one patient(s) showing decreases of 50-89% and 90-99%, respectively, while 10 patients were seizure free. The frequency of other seizures types likewise decreased in 60% of patients. Four patients achieved a seizure-free status for all seizure types. At follow-up, no SE or generalised convulsions lasting ≥5 min were detected in the patients. Thus, the KD reduced the frequency of SE or generalised convulsions lasting ≥5 min in these patients.
At the 3-and 6-month visits, 16 patients' (80%) caregivers reported improvements in patient cognition. Caregivers reported improvements in cognition in the form of increased alertness, attention, and memory. Regarding AED usage, four patients without any seizures discontinued the use of one AED at 4 months after KD initiation, while the other patients did not alter their AED regimen during the entire 6-month KD. 
Adverse events and tolerance
Short
Compared with cognition before KD: → (no change); ↑ (improvement); ↓ (regression). levels were > 1.7 mmol/L but < 5.6 mmol/L. Hypercholesterolaemia was observed in 30%(6/20) and 40%(8/20) of patients at 3 and 6 months, respectively. Cholesterol levels remained stable, with a total cholesterol value > 5.72 mmol/L. Moderate growth impairment was observed in two patients. Kidney stones, hypocalcaemia, and cardiac abnormalities were not detected in any of the patients at the 6-month follow-up visit.
Discussion
To our knowledge, only a few clinical studies have evaluated the efficacy of the KD in children with DS [9] [10] [11] 18] . Further, research on the utility of the KD as a treatment for Chinese patients with DS is scarcely found in the literature. Considering the large size of the Chinese population, and consequently the large number of Chinese patients with DS, clinical data on this topic are needed. Therefore, the present study evaluated the efficacy and tolerability of the KD in Chinese patients with DS, with particular emphasis on generalised convulsions, specifically general convulsion seizures lasting ≥5 min and SE.
It is known that DS is almost invariably refractory to most conventional AEDs. Sodium channel-blockers can aggravate seizures and even induce SE. Although prior research has indicated that stiripentol administered with clobazam and valproate yields a response rate of 66.7% among Japanese patients with DS [6] , stiripentol and clobazam are despondently unavailable in China. Most response rates for AEDs are even lower; for instance, 52% of patients on valproate exhibited seizure decreases of > 50%, while 57% of patients on topiramate showed > 50% decreases in seizure frequency, although the patients experienced adverse effects of anorexia and behavioural problems. Clobazam and clonazepam showed efficacies of 44% and 43%, respectively, among Chinese SCN1A-positive patients with DS [19] . In the present study, 17 of the 20 (85%) patients with DS in whom several AEDs had failed responded well to the KD (generalised convulsion seizure decreases of ≥50%). Further, 12of 20 (60%) patients showed decreases in other seizures types at month 6 after KD initiation, and four patients achieved a seizure-free status for all seizure types. Hence, we found that the KD had a better efficacy for the treatment of DS than did the various currently available AEDs that the patients were receiving prior to KD initiation.
In 2005, Caraballo et al. [9] first evaluated the efficacy of the KD in 20 patients with DS, 13 (65%) of whom exhibited a > 50% decrease in seizure frequency, and no differences were found regarding the effects of the KD on different seizure types. However, here, the main outcome of interest was the frequency of generalised convulsions, as recorded by patients' caregivers. As such, our research revealed a reduction specifically in the frequency of general convulsions from before to after KD initiation. Compared with previously reported studies, the current study showed an overall better effect of KD treatment in reducing generalised convulsion frequency, with 85% of patients demonstrating decreases of ≥50%. We emphasised the effects on generalised convulsions for the following three reasons. First, generalised convulsions are often prolonged or even result in convulsive SE. Second, generalised convulsions occur throughout the evolution of the disease in all patients, allowing for better comparisons with the baseline seizure frequency. Third, caregivers can easily identify and record generalised convulsions. Indeed, although doctors and clinical professionals can count the occurrences of other seizure types, such as transient myoclonic seizures and atypical absence seizures, it is difficult for general caregivers to perform this, as such seizures are only present in some patients, may appear at different ages, and are sometimes barely discernible.
Before KD initiation, 15 patients had SE, and 20 patients had generalised seizures of ≥5 min in duration. Encouragingly, after 3 and 6 months of the KD, none of the patients exhibited SE or prolonged general convulsions. Thus, the KD reduced the frequency of prolonged seizures and SE in patients with DS. Previously, Kossoff [20] reported that the KD is being considered for SE cases with increasing frequency throughout the world. According to their report, 10 retrospective publications since 2008 have demonstrated benefits in 32 children and adults with SE, of whom 25 (78%) became seizure free [20] . The experience of O'Connor et al. [21] also suggests that the KD can be useful in managing refractory SE in children. Additionally, Dressler et al. [11] reported that the seizure type that responded the best to the KD was SE, noting that SE was not observed in any patient while on the KD. Similarly, our findings support that the KD can effectively prevent prolonged seizures and SE in patients with DS.
A greater degree of cognitive and behavioural impairment has been linked to the frequency and duration of convulsive seizures. Available data suggest that the KD exerts neuroprotective effects that improve cognitive and behavioural functioning in patients with epilepsy. For instance, a previous study demonstrated that the KD enhanced cognitive function and improved abnormal behaviours, including overexcitement, in children with DS [5] . The parental report measures of cognitive function used in this study indicated that children showed better cognitive functioning, including increased alertness, attention, and memory, after vs. before KD initiation. Thus, our data confirm prior findings showing that the KD improves cognitive function in patients with DS.
The KD seems to be relatively safe compared to other treatments reported in the literature, and only a few side effects of the KD were noted in our study. Most adverse effects were transient and could be controlled without withdrawing the patient from the KD. Hypercholesterolaemia and hypertriglyceridaemia were observed in some patients over the course of treatment. No studies employing the KD as a treatment for patients with DS, including the present study, showed delayed effects of the KD on the function of the cardiovascular system. Moreover, we did not identify any progressive bone mineral content loss, renal stones, iron-deficiency anaemia, or cardiomyopathy during the 6-month treatment period; nevertheless, studies with longer follow-up times are needed.
Several limitations of this study should be noted, including the small sample size and short follow-up period. Further, we only evaluated a few seizure types, and the cognitive function outcomes were measured subjectively. Therefore, additional prospective studies that include a larger number and greater diversity of patients, objective assessments of cognition, and long-term evaluations are required to confirm our findings.
Conclusion
Collectively, our findings support that the KD is an effective therapy for DS in terms of tolerability and efficacy. The KD reduced the frequency of general convulsions in patients with medically intractable DS. Particularly, the KD reduced the frequency of emergencies in patients with DS and decreased the risk of nerve injury due to SE.
